secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001213900-23-066456
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics reports Q2 2023 results; IPO nets $20.5M, INT230-6 shows survival benefit in sarcoma
--------------------------------------------------------------------------------

- Closed upsized IPO of 3.9M shares at $5.00/sh, net proceeds $20.5M; cash runway extended into early Q3 2025.
- INT230-6 data at ASCO: median OS 21.3 months in refractory metastatic sarcoma vs historical 7-10 months.
- Net operating loss $1.2M in Q2 2023 vs $1.9M in Q2 2022; non-operating loss $2.3M from convertible debt discount included.
- Plan to file IND for phase 3 study of INT230-6 in soft tissue sarcoma by end of 2023.
- Additional INVINCIBLE breast cancer data expected by year-end; phase 2/3 program planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/0001213900-23-066456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000121390023066456/ea183398-8k_intensity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-066456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer